Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Merks group

The focus of the Merks group is to answer key clinical questions in pediatric sarcoma treatment with the aim to improve cure and quality of life. As Chair of the European pediatric Soft tissue sarcoma Study Group (EpSSG) and Vice-Chair of the Executive Board of the EuroEwing Consortium (EEC) Merks’ aim is to coordinate, design and implement international prospective clinical trials, including translational research, focused on sarcoma across the pediatric and young adult age range. Research in pediatric sarcoma pre-eminently is a multidisciplinary collaboration including a diversity of basic, translational and clinical research partners.
  • PI: Dr. Hans Merks
Research Lines
  • The Pediatric Sarcoma Imaging Group aims to design and implement innovative imaging studies to identify early biomarkers that predict outcome in clinical trials and individual patient care, and optimize staging. This entails a close collaboration with the PROVIDI lab of Alexander Leemans (Imaging Sciences Institute UMCU), Simone ter Horst and Bart de Keizer (Radiology UMCU) and prof. dr. Rick van Rijn (AUMC)
  • Individualized prediction of treatment-induced facial deformities and functional impairments for children with head and neck rhabdomyosarcoma (HN RMS). This international (US, Fr, UK) multicenter multidisciplinary project aims to develop a decision support model that enables well-informed shared multimodal treatment decision making based on Adverse Event prediction for individual HN RMS patients.
  • Functional outcome and quality of life after local therapy for bone sarcoma in children. This multidisciplinary project aims to describe functional outcome and quality of life in bone sarcoma survivors with the ultimate goal to generate a prediction model for local therapy related adverse effects and functional outcome.
  • Recognition of cancer predisposition syndromes (CPS). The aim is to develop strategies to guarantee recognition of established CPS in childhood cancer patients and identify potential new CPS in collaboration with the Kuiper group and Raoul Hennekam (AUMC).
Hans Merks - PI

 
 

Merks group